Bionano Genomics Inc (BNGO)
$0.98
0.03 (3.52%)
BNGO Stock Quote Delayed 30 Minutes
Bionano Is Not the Genomics Stock To Bet On
Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
274.51M
PE Ratio
-0.18
EPS
-5.54
Volume (Avg. Vol.)
369,131
Day's Range
$0.95 - $1.01
52-Week Range
$0.71 - $8.20
Dividend & Yield
N/A (N/A)
BNGO Stock Predictions, Articles, and Bionano Genomics Inc News
The Critics Are Wrong About Bionano Stock
The critics of Bionano are greatly underestimating the vast potential of Saphyr and of BNGO stock for long-term investors.
This Analyst’s Saphyr Calculations Suggest Buying Bionano While It’s Down
If BNGO stock reaches Oppenheimer’s price target, investors are looking at a return of more than 300%, plus long-term growth potential.
Bionano Genomics Proves Not Everything Genetic is Gold
Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes.
Wait for Bionano Stock to Fall Further Before Buying
BNGO stock is breaking down following the latest earnings report, and there are no major catalysts to push shares up in the short term.
Bionano’s Is on Track for Growth Thanks to Saphyr
BNGO stock beats analyst forecasts yet again. Flush with cash and with Saphyr installations rising, this stock remains a high potential play.
With Progress on Multiple Fronts, Bionano Genomics Stock Is Great Buy Here
Bionano's acquisition of a software company makes Saphyr more attractive, and studies should result in insurers reimbursing those who use the system. BNGO stock is a buy.
Bionano Genomics Is Still Set to Pay Off Big for Patient Investors
It may take time for it to potentially move back to its all-time high of $15.69 per share. But given that's nearly triple what it trades today, patience could pay off big with BNGO stock.
Bionano Genomics’ Latest Software Business Acquisition Adds Immense Value
BNGO stock isn't a darling of the markets at the moment, but Bionano continues to advance its stature in the optical genome mapping niche.
Bionano Genomics Stock Looks Ready to Reward Patient Investors
BNGO stock is down 25% since the beginning of the year. But as the company begins to deliver consistent revenue, a prudent investment may be rewarded.
BNGO Stock: The Big Acquisition News Sending Bionano Genomics Soaring
Bionano has just made a deal that will help it secure a spot among biotech companies riding the wave of the current boom. BNGO stock is up.
Groundbreaking Tech Makes Bionano Genomics Look Better Than Ever
Off and on the price chart, Bionano Genomics could be the next big thing in genomics with multiple catalysts for BNGO stock.
BNGO Stock: What Is Driving Bionano Genomics Higher Today?
Today, investors in Bionano Genomics and BNGO stock are cheering some positive clinical trial data around optical genome mapping.
Bionano Genomics Remains Promising With Global Product Adoption
BNGO stock has been stuck in a range, but its next move should be to the upside based on Bionano's breakthrough genome mapping system.
The Price Is Right for BioNano Genomics Given Saphyr’s Potential
With its Saphyr system seeing adoption ramp up, the long-term growth potential for BNGO stock is considerable.
Bionano Stock Will Soar as the Company’s Diagnostic System Catches On
As more payors reimburse labs for using Bionano's Saphyr device, the company's financial results will improve, lifting BNGO stock.
Faster and Better Clinical Outcomes Make the Case for Bionano Genomics
Bionano Genomics is mastering the science of genome mapping, while a reduced-price BNGO stock has a clear path forward for investors.
Bionano’s Technology Is Interesting, But Its Earnings Are Uninspiring
Bionano could become a decent testing company within its niche. However, BNGO stock has run far ahead of the company's fundamentals.
Weak Fundamentals Prove There Is No Reason to Buy Bionano Genomics
Bionano Genomics is risky and its valuation does not justify its price. There is no compelling argument for a buy in BNGO stock.
You’d Be Wrong to Paint Bionano Genomics Stock With the Meme-Stock Brush
With Bionano's disruptive tool, Saphyr, poised to revolutionize the DNA analysis sector, investors should definitely look to buy BNGO stock on its recent dip.
